1611 related articles for article (PubMed ID: 28109892)
21. The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism.
Chambel SS; Santos-Gonçalves A; Duarte TL
Biomed Res Int; 2015; 2015():597134. PubMed ID: 26120584
[TBL] [Abstract][Full Text] [Related]
22. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
[TBL] [Abstract][Full Text] [Related]
23. Lipid mediators of liver injury in nonalcoholic fatty liver disease.
Liangpunsakul S; Chalasani N
Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G75-G81. PubMed ID: 30383414
[TBL] [Abstract][Full Text] [Related]
24. Nonalcoholic Steatohepatitis.
Suzuki A; Diehl AM
Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
[TBL] [Abstract][Full Text] [Related]
25. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
26. [Cholesterol metabolism and non-alcoholic steatohepatitis].
Ma ZZ; Lu LG
Zhonghua Gan Zang Bing Za Zhi; 2016 Aug; 24(8):623-627. PubMed ID: 27788713
[TBL] [Abstract][Full Text] [Related]
27. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.
Amrutkar M; Cansby E; Nuñez-Durán E; Pirazzi C; Ståhlman M; Stenfeldt E; Smith U; Borén J; Mahlapuu M
FASEB J; 2015 Apr; 29(4):1564-76. PubMed ID: 25609431
[TBL] [Abstract][Full Text] [Related]
28. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.
Simon Y; Kessler SM; Gemperlein K; Bohle RM; Müller R; Haybaeck J; Kiemer AK
World J Gastroenterol; 2014 Dec; 20(47):17839-50. PubMed ID: 25548482
[TBL] [Abstract][Full Text] [Related]
29. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression.
Dallio M; Sangineto M; Romeo M; Villani R; Romano AD; Loguercio C; Serviddio G; Federico A
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406763
[TBL] [Abstract][Full Text] [Related]
30. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
[TBL] [Abstract][Full Text] [Related]
31. Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease.
Teng T; Qiu S; Zhao Y; Zhao S; Sun D; Hou L; Li Y; Zhou K; Yu X; Yang C; Li Y
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887189
[TBL] [Abstract][Full Text] [Related]
32. The Natural Course of Non-Alcoholic Fatty Liver Disease.
Calzadilla Bertot L; Adams LA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
[TBL] [Abstract][Full Text] [Related]
33. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
Panera N; Gnani D; Crudele A; Ceccarelli S; Nobili V; Alisi A
World J Gastroenterol; 2014 Nov; 20(41):15079-86. PubMed ID: 25386056
[TBL] [Abstract][Full Text] [Related]
34. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
[TBL] [Abstract][Full Text] [Related]
35. The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update.
Hliwa A; Ramos-Molina B; Laski D; Mika A; Sledzinski T
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34199035
[TBL] [Abstract][Full Text] [Related]
36. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
[TBL] [Abstract][Full Text] [Related]
37. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathways of nonalcoholic fatty liver disease development and progression.
Bessone F; Razori MV; Roma MG
Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
[TBL] [Abstract][Full Text] [Related]
39. RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
Afonso MB; Rodrigues PM; Mateus-Pinheiro M; Simão AL; Gaspar MM; Majdi A; Arretxe E; Alonso C; Santos-Laso A; Jimenez-Agüero R; Eizaguirre E; Bujanda L; Pareja MJ; Banales JM; Ratziu V; Gautheron J; Castro RE; Rodrigues CMP
Gut; 2021 Dec; 70(12):2359-2372. PubMed ID: 33361348
[TBL] [Abstract][Full Text] [Related]
40. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
